Bydgoszcz

• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early … Halted
  2024-518523-30-00 4 2023-11-08 early Alzheimer’s disease
• A Phase 2, Double-Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of EE and Maintenance of Healed EE in Pediatric … Ended
  2022-501350-11-00 4 2026-04-09 Erosive Esophagitis
• Multicenter study on patient’s ability to independently and safely use of Sildenafil 100 mg for erectile dysfunction. Ended
  2025-522923-81-00 6 2026-02-17 Erectile dysfunction
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended
  2024-513435-24-01 4 2025-06-03 Neuropathic Pain; Distal Sensory Polyneuropathy
• A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder … Ended
  2024-511549-20-00 4 2025-04-22 Dermatitis atopic
• A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in … Ended
  2024-510826-16-00 5 2025-04-07 Rheumatoid Arthritis
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• Impact of trimetazidine on endothelial function and biomarkers correlating with the prognosis of heart failure with preserved ejection fract … Ended
  2023-506138-65-00 6 2025-02-20 Heart failure with preserved ejection fraction
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in … Ended
  2024-510945-32-00 5 2024-12-17 Rheumatoid arthritis
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended
  2024-514559-13-00 10 2024-11-26 Focal Epilepsy
• Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome Ended
  2024-515060-32-00 5 2024-11-22 Takotsubo syndrome
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended
  2023-507563-19-00 5 2024-11-05 Thyroid eye disease
• A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB … Ended
  2023-507376-50-00 1 2024-09-27 Ulcerative Colitis
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane … Ended
  2023-504942-75-01 5 2024-08-22 Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or witho
• Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient gly … Ended
  2023-508924-36-00 5 2024-08-20 Type 2 diabetes mellitus (T2DM)
• A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended
  2023-508821-28-00 4 2024-08-14 Migraine
• Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat … Ended
  2023-508170-28-00 4 2024-08-07 alcohol-related liver disease

Showing 529–552 of 707 trials